However, when further stratified by type of FLT3 mutation, those with FLT3-ITD-mutated AML had particularly poor outcomes (median OS 9.9 months), which was shorter than the FLT3 wild type population (median OS 14.7 months) and the FLT3-TKD-mutated population (median OS 19.2 months). This evidence concerns the gene FLT3 and acute myeloid leukemia.